Key facts
- This page summarizes Steven Gillis's Form 4 filing for Codiak BioSciences, Inc..
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 21 Feb 2023, 15:31.
Key filing fact
Ownership activity is grounded in SEC Form 4 disclosures.
Shares, units, or other non-derivative securities reported in this filing.
Options Exercise
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
Options Exercise
Additional SEC filing notes
Footnote F1
Restricted stock units ("RSUs") convert into common stock on a one-for-one basis.
Footnote F2
Each RSU represents a contingent right to receive one share of common stock.
Footnote F3
On February 16, 2022, the reporting person was granted 8,750 RSUs, which vested in full on February 16, 2023.